Incyte CorporationINCYNASDAQ
Loading
A mid-sized company, with exceptional profitability, showing strong growth valued in line with the market.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic.
Comprehensive financial statement data for deep analysis
| Metric | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 93.7% | 92.5%↓1.3% | 91.5%↓1.2% | 91.1%↓0.4% | 91.5%↑0.4% |
| Operating Margin | 21.3% | 17.7%↓17.3% | 17.6%↓0.1% | 1.9%↓89.3% | 26.1%↑1282.1% |
| Net Margin | 31.8% | 10.0%↓68.4% | 16.2%↑61.1% | 0.8%↓95.2% | 25.0%↑3154.4% |
| Earnings Yield | - | - | - | - | - |